Frontier Swings to Q4 Loss, Revenue Higher-May 2024-www.financetom.com

Frontier Swings to Q4 Loss, Revenue Higher

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Frontier Swings to Q4 Loss, Revenue Higher

Feb 20, 2025 2:12 PM

04:34 PM EST, 02/20/2025 (MT Newswires) -- Frontier Communications Parent ( FYBR ) reported a Q4 net loss late Thursday of $0.47 per diluted share, swinging from earnings of $0.07 from a year earlier.

Analysts polled by FactSet expected loss of $0.21.

Revenue for the quarter ended Dec. 31 was $1.51 billion, up from $1.43 billion a year earlier.

Analysts surveyed by FactSet expected $1.47 billion.

Previous page： BRIEF-Diamondback In Talks To Buy Permian Producer Double Eagle - WSJ Next page： --Louisiana-Pacific Lifts Quarterly Dividend 8% to $0.28 a Share, Payable March 13 to Holders on Feb. 27

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Diamondback In Talks To Buy Permian Producer Double Eagle - WSJ

Feb 14, 2025

Feb 14 (Reuters) - * DIAMONDBACK IN TALKS TO BUY PERMIAN PRODUCER DOUBLE EAGLE - WSJ * DEAL COULD VALUE DOUBLE EAGLE AT MORE THAN $5 BILLION IS EXPECTED IN COMING DAYS- WSJ Source text: https://tinyurl.com/2bspkm3f ...

--Louisiana-Pacific Lifts Quarterly Dividend 8% to $0.28 a Share, Payable March 13 to Holders on Feb. 27

Feb 14, 2025

12:14 PM EST, 02/14/2025 (MT Newswires) -- Price: 111.69, Change: -0.58, Percent Change: -0.52 ...

AstraZeneca's Bladder Cancer Treatment Improves Survival in Phase 3 Trial

Feb 14, 2025

12:06 PM EST, 02/14/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that results from its phase 3 trial showed its bladder cancer treatment candidate, Imfinzi, improved event-free survival and overall survival in patients with muscle-invasive bladder cancer. The benefits were observed regardless of whether patients achieved a pathologic complete response, according to the company. Patients in the study...

DexCom Likely to Sustain Stability in 2025, Morgan Stanley Says

Feb 14, 2025

12:08 PM EST, 02/14/2025 (MT Newswires) -- DexCom's ( DXCM ) Q4 results demonstrated the company's stable performance, with expectations for it to continue, Morgan Stanley said in a Friday note. After a rockier couple quarters, the print was encouraging in as much as it demonstrated stability, and we came away with expectations for more of the same with a...